News and Trends 29 Jan 2018 London Tops Europe for Life Sciences Investment in 2017 Investment in London’s life sciences companies reached almost £1B in 2017, beating the likes of Berlin and Paris to top spot. A new study has found that London’s life sciences industry received the most investment out of any city in Europe in 2017. Over the last 5 years, companies in the capital have raised £2.8Bn (€3.2Bn), with £909M […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 Mapping of the Axolotl’s Genome Boosts the Regenerative Medicine Field Salamanders have long been a useful model for regenerative medicine due to their ability to regrow entire limbs. Now, scientists have found the genes that drive the process. Scientists in Vienna, Dresden, and Heidelberg are the first to completely map the genome of the axolotl salamander. Despite its popularity as a biological model and use for […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 29 Jan 2018 Meet the CEO of the Other Big Biotech Acquisition Target in 2017 Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and the company do it, with only one early-stage candidate? There were exactly two notable biotech acquisitions in Europe last year: Actelion and a smaller startup based in Munich called Rigontec, which had an RNA candidate […] January 29, 2018 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2018 Biology and Art Take Over the Berlin Central Station The art installation Relationscape connected many Berlin commuters with the future of biology at the capital’s central station. This week, the daily commuters of the German capital got a chance to come face to face with the world of biology. At the entrance of the Berlin Central Station, a huge building made of steel, glass […] January 27, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2018 New British Spinout May Get Snapped Up by Allergan for $400M KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […] January 26, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2018 Update: Bionic Implant Restores Vision in a Human for the First Time Update (26/01/2018): A first patient was implanted with Pixium Vision’s PRIMA bionic device. A month after implantation, the device was activated and the patient, who suffered from severe vision loss due to age-related macular degeneration (AMD), reported “a first perception of light from the central zone where there was none previously,” according to principal investigator Dr. […] January 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 26 Jan 2018 This Danish Biotech is Working on Better, Safer Drugs for Cardiac Arrhythmia This week, we’re visiting Acesion Pharma in Copenhagen, a biotech that is developing more effective, safer drugs for atrial fibrillation, the most common form of cardiac arrhythmia. Mission: Since being founded in 2011, Acesion has already caught our attention, being named as one of our top biotechs in Copenhagen. The biotech focuses on the development of […] January 26, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Novartis Will Bring US Gene Therapy for Blindness to Europe The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for commercialization rights outside the US. Novartis first marked out its position as a gene therapy leader in 2012 when it threw its hat into the CAR-T ring. Just a few months after the FDA approved […] January 25, 2018 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 25 Jan 2018 What Happened to the Plans for a Smart Contact Lens for Diabetics? Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but a recent study predicts that the market will pick up this year introducing innovative products to the consumer market: according to CCS Insight, the market for […] January 25, 2018 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus In an early study at Queen Mary University in London, a modified flu virus has been able to block the growth of pancreatic cancer. For the first time, researchers at Queen Mary University, London, have shown that pancreatic cancer can be targeted using a modified flu virus. During a study, published in Molecular Cancer Therapeutics, […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email